Pulmonary Arterial Hypertension (PAH) Market in China 2023

Pulmonary Arterial Hypertension (PAH) Market in China 2023

Pulmonary Arterial Hypertension (PAH) is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It occurs when the pulmonary arteries, which carry blood from the heart to the lungs to pick up oxygen, become narrowed and stiff, resulting in increased resistance to blood flow and higher blood pressure in the arteries. PAH can cause symptoms such as shortness of breath, fatigue, chest pain, dizziness, and fainting. It can also lead to complications such as heart failure, blood clots, and infections. The pulmonary arterial hypertension market in China is projected to rise by USD 913.9 million by 2029, according to the latest market study results. It is anticipated to expand at a CAGR of 39.27 percent during the forecast period.

This industry report offers market estimates of the China market, followed by a detailed analysis of the region. The China market data on pulmonary arterial hypertension can be segmented by region: Central South China, East China, North China, Northeast China, Northwest China, Southwest China.

The report also includes the profiles of leading companies such as Actelion Pharmaceuticals Ltd., Bayer AG, Beijing Tide Pharmaceutical Co. Ltd., GlaxoSmithKline plc, United Therapeutics Corporation.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
  • Get a detailed picture of the China Pulmonary Arterial Hypertension Market
  • Identify segments/areas to invest in over the forecast period in the China Pulmonary Arterial Hypertension Market
  • Understand the competitive environment, the market’s leading players
  • The market estimate for ease of analysis across scenarios in Excel format.
  • Strategy consulting and research support for three months.
  • Print authentication provided for the single-user license.

  • Part 1. Summary
    Part 2. Introduction
    Study period
    Geographical scope
    Market segmentation
    Part 3. Pulmonary arterial hypertension market overview
    Part 4. Market breakdown by region
    Central South China
    East China
    North China
    Northeast China
    Northwest China
    Southwest China
    Part 5. Key companies
    Actelion Pharmaceuticals Ltd.
    Bayer AG
    Beijing Tide Pharmaceutical Co., Ltd.
    GlaxoSmithKline plc
    United Therapeutics Corporation
    Part 6. Methodology

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings